Department of Colorectal Surgery, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Department of Surgery, University of Adelaide, Adelaide, South Australia, Australia.
Colorectal Dis. 2017 Nov;19(11):973-979. doi: 10.1111/codi.13724.
The aim was to determine whether the addition of additional cycles of chemotherapy during the 'wait period' following neoadjuvant chemoradiotherapy for rectal cancer improves the pathological complete response (pCR) rate.
Rectal cancer patients were randomly allocated either to a standard 10 week wait period before surgery (standard chemoradiotherapy, SCRT) or to receive three cycles of fluorouracil based chemotherapy following chemoradiotherapy during a similar 10 week wait (extended chemoradiotherapy, XCRT). The primary end-point was pCR as determined by blinded pathological assessment.
Forty-nine patients were randomized (SCRTn = 24, XCRTn = 25). pCR occurred in 10 patients overall but there was no significant difference in pCR between the groups (SCRTn = 6, XCRTn = 4, P = 0.49).
The addition of three cycles of 5-fluorouracil/leucovorin in a 10 week wait period after conventional chemoradiotherapy seems to result in similar pCR rates in patients with locally advanced rectal cancer based on this small randomized trial.
旨在确定在新辅助放化疗后“等待期”期间增加额外的化疗周期是否能提高直肠肿瘤的病理完全缓解(pCR)率。
将直肠肿瘤患者随机分为手术前标准 10 周等待期(标准放化疗,SCRT)组或在类似的 10 周等待期内接受放化疗后三个周期的氟尿嘧啶为基础的化疗(扩展放化疗,XCRT)组。主要终点是通过盲法病理评估确定的 pCR。
共有 49 名患者被随机分配(SCRTn=24,XCRTn=25)。总的来说,10 例患者出现 pCR,但两组之间的 pCR 无显著差异(SCRTn=6,XCRTn=4,P=0.49)。
根据这项小型随机试验,在常规放化疗后 10 周的等待期内增加三个周期的 5-氟尿嘧啶/亚叶酸似乎使局部晚期直肠肿瘤患者的 pCR 率相似。